کارآزمایی واکسن ملانوم مرک نشان دهنده کاهش عود یا مرگ ناشی از سرطان پوست است

Merck's melanoma vaccine trial shows reduced recurrence or death from skin cancer

Merck presented its mRNA melanoma vaccine trial data at a European cancer conference this weekend. Results are promising: The vaccine reduces recurrence and death alongside an immunotherapy drug.